UK markets closed

Zur Rose Group AG (ZRSEF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
362.000.00 (0.00%)
At close: 2:39PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close362.00
Open359.00
Bid0.00 x 0
Ask0.00 x 0
Day's range362.00 - 362.00
52-week range94.27 - 547.00
Volume51
Avg. volume491
Market cap4.09B
Beta (5Y monthly)0.44
PE ratio (TTM)N/A
EPS (TTM)-16.64
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Zur Rose Group strengthens Group Management: Madhu Nutakki to become Chief Technology Officer

    EQS Group-News: Zur Rose Group AG / Key word(s): Personnel15.06.2021 / 07:00 Frauenfeld, 15 June 2021 Press release Zur Rose Group strengthens Group Management: Madhu Nutakki to become Chief Technology OfficerMadhu Nutakki will take on the newly created position of Chief Technology Officer (CTO) of the Zur Rose Group on 1 August 2021. As a member of the Group Management, Madhu Nutakki will be responsible for establishing a flexible Group technology platform, which will develop into Zur Rose's Eu

  • EQS Group

    Faster and more secure access to the gematik e-prescription with eHealth-Tec: Compatible software development kit for software providers

    The e-prescription will be made mandatory nationwide on 1 January 2022By October 2021, doctors’ practices, pharmacies and hospitals must have access to the gematik e-prescriptioneHealth-Tec enables software providers to connect their customers on scheduleBerlin, 28/05/2021 – The digitalisation of the healthcare system in Germany will gain momentum in the coming weeks and months. Electronic patient files, electronic prescriptions, digital vaccination certificates: major challenges for the development resources of administrative and information system providers.eHealth-Tec (eht), subsidiary of the Swiss Zur Rose Group and market leader in the digitalisation of the prescription process in Germany, has developed a compatible Software Development Kit (SDK), enabling providers of practice and pharmacy management systems as well as hospital information systems to easily upgrade their software to the required technical level if they are not yet connected to the specialist e-prescription service. The tools are tried-and-tested: The SDK has already been deployed in the biggest e-prescription project in Germany and at various pharmacies and telemedicine providers.Whether connecting to the telematic infrastructure, connecting the Qualified Electronic Signature or identity management, the SDK developed by eHealth-Tec simplifies implementation and combines many individual steps in a stringent process - in compliance with the highest security standards and all requirements laid down by gematik. Tobias Leipold, CEO of eHealth-Tec GmbH, points out: “Through our variable interface management, we ensure continuous updates and upgrades – the software providers make themselves independent of all minor adjustments made by gematik. Our technical and professional support also enables convenient integration into the existing administration and information systems.”Further information on the SDK at https://e-rezept-sdk.ehealth-tec.de/sdk or 0800 5004800.About eHealth-Tec: eHealth-Tec (eht) uses structured digital data to develop solutions for networking medical institutions at the highest technical and medical level. Through the eht applications, the digital medical care process is to be fully covered: from the doctor to the clinic or pharmacy to other medical stakeholders and patients. The practical relevance and user-friendliness of the innovative software solutions form the basis of the eht work. The vision is to actively shape the digital future of healthcare itself and in many strategic partnerships. eht is already a pioneer in e-prescriptions and emergency room information software. Thanks to its multi-professionalism and many years of experience in the healthcare sector, eht guarantees optimal support for all stakeholders.Contact information for Sales at eHealth-Tec:E-mail: vertrieb@ehealth-tec.de Telephone: 0800 5004800 Monday to Friday from 8.a.m. to 8 p.m.Press contact eHealth-Tec: Torben Bonnke Telephone: +49 30 2122236 12 Mobile: +49 171 864 888 1 Email: presse@ehealth-tec.de

  • EQS Group

    Annual General Meeting of Zur Rose Group AG: Shareholders approve all proposals

    EQS Group-News: Zur Rose Group AG / Key word(s): AGMEGM29.04.2021 / 18:00 Frauenfeld, 29 April 2021 Press release 2021 Annual General Meeting of Zur Rose Group AGShareholders approve all proposalsThe 28th Annual General Meeting of Zur Rose Group AG took place today in Zurich. Due to the ongoing extraordinary situation in connection with the corona pandemic, the meeting was again held without the personal participation of the shareholders. The shareholders of Zur Rose Group AG were able to exercise their rights at the Annual General Meeting exclusively through the independent proxy. In total, 5,198,863 shareholder votes, equivalent to 49.38 per cent of the share capital or 77.05 per cent of the shares entitled to vote, were represented by the independent proxy. The Board of Directors would like to thank all those who exercised their shareholder rights in this way.The shareholders approved the Management Report, the Annual Financial Statements and Consolidated Financial Statements for 2020 and the appropriation of retained earnings and ratified the actions taken by the Board of Directors and Group Management during the year. The Chairman of the Board of Directors and the members of the Board of Directors standing for re-election as well as all members of the Compensation Committee were confirmed for a further term of office of one year. Prof. Dr. Andréa Belliger was newly elected to the Board of Directors. Further, the Annual General Meeting approved the proposed maximum total amounts of compensation for the members of the Board of Directors and the Group Management. In addition, the compensation report for the 2020 financial year was approved in a consultative vote. Ernst & Young AG as auditors and Fürer Partner Advocaten KIG as independent proxy were confirmed for a further term of office of one year.Furthermore, the shareholders approved the proposal to create authorized share capital in the nominal amount of CHF 31,579,080, corresponding to 10 per cent of the registered share capital, and to increase the conditional share capital for financing, acquisitions and other purposes to CHF 31,579,080. At the same time, the shareholders resolved to include a provision in the Articles of Association pursuant to which the total number of shares that may be issued from authorized and conditional share capital is limited to a total of 10 per cent of the current registered share capital (corresponding to 1,052,636 registered shares).Likewise, the shareholders resolved an amendment to the Articles of Association granting the Board of Directors flexibility with respect to the designation of the Compensation Committee.The minutes with the detailed voting results will be available at "zurrosegroup.com > Investors & Media > Annual General Meeting" as of 30 April 2021.Investors and analyst contactChristoph Herrmann, Head of Investor RelationsEmail: ir@zurrose.com, phone: +41 58 810 11 49Media contactLisa Lüthi, Head of Group CommunicationsEmail: media@zurrose.com, phone: +41 52 724 08 14AgendaA Capital Markets Day in virtual format will take place on 16 June 2021. Invitation and agenda will follow at a later date.18 August 2021 Half-Year Results21 October 2021 Q3 Trading UpdateZur Rose GroupThe Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris, and employs more than 2,200 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving more than 11 million active customers in core European markets, Zur Rose generated revenue of CHF 1,752 million (including external revenue) in 2020.With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.End of Media Release Language: English Company: Zur Rose Group AG Walzmühlestrasse 60 8500 Frauenfeld Switzerland Phone: +41 52 724 08 14 Internet: www.zurrosegroup.com ISIN: CH0042615283 Listed: SIX Swiss Exchange EQS News ID: 1190829 End of News EQS Group News Service